Company Filing History:
Years Active: 2003
Title: Douglas Wilkinson – Innovator in Cyclophilin Binding Compounds
Introduction
Douglas Wilkinson, an accomplished inventor based in Baltimore, MD, has made significant contributions to the field of pharmaceuticals. His innovative work revolves around the development of compounds that target cyclophilin-type immunophilin proteins, addressing various medical disorders through novel therapeutic applications.
Latest Patents
Wilkinson holds a patent titled "Trisubstituted carbocyclic cyclophilin binding compounds and their use." This invention relates to small, non-peptidic organic compounds that exhibit a strong affinity for cyclophilin (CyP)-type proteins. Moreover, the patent encompasses pharmaceutical compositions that integrate these compounds, emphasizing their potential to inhibit peptidyl-prolyl isomerase activity and their application in research and therapeutics.
Career Highlights
Douglas Wilkinson is associated with Guilford Pharmaceuticals, Inc., where he continues to push the boundaries of pharmaceutical research. His work in creating compounds with therapeutic potential showcases his dedication to improving medical treatments and understanding complex biological interactions.
Collaborations
Throughout his career, Wilkinson has collaborated with esteemed colleagues, including Yong-Qian Wu and Sergei Belyakov. These partnerships exemplify the collaborative spirit of innovation in scientific research and the importance of teamwork in advancing new medical solutions.
Conclusion
In summary, Douglas Wilkinson is a notable inventor whose advancements in cyclophilin binding compounds hold promise for addressing various medical conditions. His patent not only signifies a milestone in pharmaceutical research but also highlights the ongoing efforts to innovate and improve therapeutic options for patients worldwide.